SCHEMBL282115

SCHEMBL282115

CN1CCN(C2CCN(c3cc[c]cc3C(F)(F)F)CC2)CC1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
RET P07949 4/20 0.39
ROS1 P08922 4/20 0.39
FLT3 P36888 4/20 0.39
EML4 Q9HC35 2/20 0.39
ALK Q9UM73 2/20 0.39
EGFR P00533 1/20 0.39
ACVR1 Q04771 4/20 0.37
ASIC3 Q9UHC3 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
FGFR3 P22607 3/20 0.34
VCP P55072 1/20 0.34
KCNH2 Q12809 2/20 0.34
L3MBTL3 Q96JM7 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL605920 0.87 ASIC3 (0.43) ALDH1A1ASIC3PDE3BPDE3AL3MBTL1
SCHEMBL282852 0.81 GAA (0.38) ALDH1A1RETROS1FLT3EML4
SCHEMBL282776 0.78 NR1H2 (0.49) ALDH1A1RETROS1FLT3EML4
SCHEMBL29649928 0.78 NR1H2 (0.49) ALDH1A1RETROS1FLT3EML4
SCHEMBL283083 0.77 DRD2 (0.47) ALDH1A1FGFR3KCNH2
SCHEMBL606331 0.77 ALDH1A1 (0.41) ALDH1A1RETROS1FLT3EML4
SCHEMBL3609693 0.77 NOTUM (0.41) PDE3BPDE3A
SCHEMBL3583431 0.76 ASIC3 (0.40) ALDH1A1ASIC3PDE3BPDE3AL3MBTL1
SCHEMBL12505776 0.75 NOTUM (0.40) ALDH1A1PDE3BPDE3A
SCHEMBL1899441 0.75 NOTUM (0.40) ALDH1A1PDE3BPDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
EP-2428508-B9 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC (JP) 2016-04-20 EP disclosed
EP-3009428-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND Astellas Pharma Inc. (JP) 2016-04-20 EP disclosed
EP-2428508-B1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC (JP) 2015-12-16 EP disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
CN-102421761-B Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC 2014-06-18 CN disclosed
EP-2428508-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND Astellas Pharma Inc. (JP) 2012-03-14 EP disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ALDH1A1 1554/4885RET 4/4885ROS1 401/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ALDH1A1 1554/4885RET 4/4885ROS1 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.